Incretin Hormones: The Link Between Glycemic Index and Cardiometabolic Diseases

Overview

Journal Nutrients

Date 2019 Aug 16

PMID 31412576

Citations 8

Authors

Teresa Salvatore

Riccardo Nevola

Pia Clara Pafundi

Lucio Monaco

Carmen Ricozzi

Simona Imbriani

Luca Rinaldi

Ferdinando Carlo Sasso

Affiliations

Soon will be listed here.

Abstract

This review aimed to describe the potential mechanisms by which incretin hormones could mediate the relationship between glycemic index and cardiometabolic diseases. A body of evidence from many studies suggests that low glycemic index (GI) diets reduces the risk for type 2 diabetes and coronary heart disease. In fact, despite the extensive literature on this topic, the mechanisms underlying unfavorable effects of high GI foods on health remain not well defined. The postprandial and hormonal milieu could play a key role in the relationship between GI and cardiovascular risk. Incretin hormones, glucagon-like peptide1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are important regulators of postprandial homeostasis by amplifying insulin secretory responses. Response of GIP and GLP-1 to GI have been studied more in depth, also by several studies on isomaltulose, which have been taken as an ideal model to investigate the kinetics of incretin secretion in response to foods' GI. In addition, extrapancreatic effects of these incretin hormones were also recently observed. Emerging from this have been exciting effects on several targets, such as body weight regulation, lipid metabolism, white adipose tissue, cardiovascular system, kidney, and liver, which may importantly affect the health status.

Citing Articles

Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.

Devasia A, Ramasamy A, Leo C Int J Mol Sci. 2025; 26(4).

PMID: 40004240 PMC: 11855529. DOI: 10.3390/ijms26041778.

Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care.

Caturano A, Galiero R, Rocco M, Tagliaferri G, Piacevole A, Nilo D Biomedicines. 2024; 12(9).

PMID: 39335551 PMC: 11429233. DOI: 10.3390/biomedicines12092039.

Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies.

Marroncini G, Naldi L, Martinelli S, Amedei A Biomedicines. 2024; 12(7).

PMID: 39061972 PMC: 11273695. DOI: 10.3390/biomedicines12071398.

An extended minimal model of OGTT: estimation of α- and β-cell dysfunction, insulin resistance, and the incretin effect.

Subramanian V, Bagger J, Harihar V, Holst J, Knop F, Villsboll T Am J Physiol Endocrinol Metab. 2023; 326(2):E182-E205.

PMID: 38088864 PMC: 11193523. DOI: 10.1152/ajpendo.00278.2023.

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives.

Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R Int J Mol Sci. 2023; 24(2).

PMID: 36675217 PMC: 9865319. DOI: 10.3390/ijms24021703.

References

Kong M, Chapman I, Goble E, Wishart J, Wittert G, Morris H . Effects of oral fructose and glucose on plasma GLP-1 and appetite in normal subjects. Peptides. 1999; 20(5):545-51. DOI: 10.1016/s0196-9781(99)00006-6. View

Kieffer T, Habener J . The glucagon-like peptides. Endocr Rev. 1999; 20(6):876-913. DOI: 10.1210/edrv.20.6.0385. View

Bertin E, Arner P, Bolinder J, Hagstrom-Toft E . Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab. 2001; 86(3):1229-34. DOI: 10.1210/jcem.86.3.7330. View

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002; 359(9323):2072-7. DOI: 10.1016/S0140-6736(02)08905-5. View

Lina B, Jonker D, Kozianowski G . Isomaltulose (Palatinose): a review of biological and toxicological studies. Food Chem Toxicol. 2002; 40(10):1375-81. DOI: 10.1016/s0278-6915(02)00105-9. View

Drucker D . Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003; 17(2):161-71. DOI: 10.1210/me.2002-0306. View

Ding K, Zhong Q, Isales C . Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: role of endothelin-1. Am J Physiol Endocrinol Metab. 2003; 285(2):E390-6. DOI: 10.1152/ajpendo.00509.2002. View

Yu M, Moreno C, Hoagland K, Dahly A, Ditter K, Mistry M . Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003; 21(6):1125-35. DOI: 10.1097/00004872-200306000-00012. View

Meier J, Gallwitz B, Salmen S, Goetze O, Holst J, Schmidt W . Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88(6):2719-25. DOI: 10.1210/jc.2003-030049. View

10.

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View

11.

Kogire M, Inoue K, Sumi S, Doi R, Yun M, Kaji H . Effects of gastric inhibitory polypeptide and glucagon on portal venous and hepatic arterial flow in conscious dogs. Dig Dis Sci. 1992; 37(11):1666-70. DOI: 10.1007/BF01299856. View

12.

Nystrom T, Gutniak M, Zhang Q, Zhang F, Holst J, Ahren B . Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004; 287(6):E1209-15. DOI: 10.1152/ajpendo.00237.2004. View

13.

Bose A, Mocanu M, Carr R, Brand C, Yellon D . Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2004; 54(1):146-51. DOI: 10.2337/diabetes.54.1.146. View

14.

Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M . GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol. 2005; 288(5):G943-9. DOI: 10.1152/ajpgi.00303.2004. View

15.

Katsuma S, Hirasawa A, Tsujimoto G . Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005; 329(1):386-90. DOI: 10.1016/j.bbrc.2005.01.139. View

16.

Abbott C, Monteiro M, Small C, Sajedi A, Smith K, Parkinson J . The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005; 1044(1):127-31. DOI: 10.1016/j.brainres.2005.03.011. View

17.

Sancho V, Trigo M, Gonzalez N, Valverde I, Malaisse W, Villanueva-Penacarrillo M . Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol. 2005; 35(1):27-38. DOI: 10.1677/jme.1.01747. View

18.

Meier J, Gethmann A, Gotze O, Gallwitz B, Holst J, Schmidt W . Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006; 49(3):452-8. DOI: 10.1007/s00125-005-0126-y. View

19.

Drucker D . The biology of incretin hormones. Cell Metab. 2006; 3(3):153-65. DOI: 10.1016/j.cmet.2006.01.004. View

20.

Sancho V, Trigo M, Martin-Duce A, Gonz Lez N, Acitores A, Arnes L . Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med. 2006; 17(6):1133-7. View